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ABSTRACT
cGMP-dependent protein kinases (PKG) are key players in intracellular second
messenger signaling within many cellular systems throughout the body. Most notably
PKG is known for its role in smooth muscle relaxation (Pfeiffer et.al, 1999). The Iα PKG
isozyme has been identified as the primary effector of the nitric oxide pathway (and
serves to be a novel drug target). To date the overall knowledge of structure and function
of PKG is lacking in terms of the mechanisms of activation and the structural
orientations that coordinate them. Recently, our laboratory has solved the crystal
structure of the regulatory domain of PKG Iα, which revealed a previously unknown αhelical domain dubbed the Switch Helix (SW) (Osborne et.al, 2011). The SW domain was
found to be a site of interprotomer communication via hydrophobic interactions between
its C-terminus and hydrophobic residues, named the nest located on the opposing
protomer. Synthetic peptides derived from the SW domain, named S-tides, dosedependently activate PKG Iα (Moon et.al, 2015). In addition, the amino acid residues of
the nest are in proximity to the cGMP binding site B. It was hypothesized that the
binding site for S-tides (nest) and the cGMP binding site B interact and are co-dependent
of one another.
The hypothesis of this thesis is the binding site for the S-tides (nest) and the
cGMP binding site B interact and are co-dependent of one another. To test this
hypothesis two aims were constructed: Aim 1: To develop an S1.5 analog that utilizes
both the nest and the B-site to increase S-tide activity, Aim 2: To explore the intricacies
of these modes of activation and how they interact with each other to obtain a better
understanding of the interplay between these two sites. First, based on the most potent
S-tide S1.5 (YEDAEAKAKYEAEAAFFANLKLSD, Ka=6 µM), two analogs were
synthesized. The peptide S2.5 which lacked the amino acids LSD at the C-terminus
showed a three-fold lower activation constant (Ka= 15 µM), although the molecule
retained its helicity as demonstrated by circular dichroism. The second analog, S3.5
contained unnatural amino acid components from a molecular modeling approach in an
effort to further increase the affinity by interacting with the adjacent cGMP binding site
B. However, S3.5 showed further reduction in activity with an activation constant of 70
µM. These findings led us to conclude that the failure of the SAR approach indicates a
different mode of S-tide activation as had been previously thought. Next, we investigated
the role of the cGMP binding site B in the mechanism of S-tide mediated PKG Iα
activation. Co-activation assays with cGMP and S1.5 demonstrated that cGMP activation
is not altered in the presence of S1.5. Furthermore, S1.5 mediated activation is negatively
affected in the presence of cGMP. These results suggest that the B-site of cGMP does not
positively enforce the S1.5 activation kinetics. Next, we employed the PKG Iα mutant
E292A, which cannot bind cGMP to the B-site (Moon et.al., 2018). Interestingly, this
mutant retains the activation kinetics of PKG Iα WT when activated via S1.5 and cGMP.
Thus, the cGMP binding site B is not crucial in the activation mechanisms of activating
PKG Iα with cGMP. Likewise, the cGMP binding site B is not crucial in the activation
mechanisms of activating PKG Iα with S1.5. To further support these findings, the PKG
Iα mutant C42A, which showed crippled cGMP activation kinetics could be activated
with S1.5 with a potency similar to wild type.
Taken together, the results in this thesis demonstrate that in contrast to the
initial hypothesis the binding sites for S-tides and cGMP, although in proximity, show no
experimental support of a positive interaction. These findings are significant as they
reveal that S1.5 mediated activation of PKG is truly independent of cGMP, thereby
providing a molecular platform for the therapeutic development of these unique
peptides.
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1.0

INTRODUCTION

1.1

Genetic Overview of PKG
Protein Kinases are a family of enzymes that are responsible for protein

phosphorylation, an extremely important cellular mechanism for transmitting
information through cells. The human kinome consists of over 500 known kinases spilt
into several distinct groups (Manning et al., 2002). The cGMP-dependent protein kinase
(Protein Kinase G, PKG) belongs to the AGC kinase family (Pearce et al., 2010). This
family contains over 60 kinases but is named after three central members PKA, PKG,
PKC (Arencibia et al., 2013). PKG, like all AGC kinases functions by transferring the γphosphate of an ATP to a serine or threonine residue of a basic substrate, making these
enzymes basophilic serine/threonine kinases (Alessi et al., 1996). As the name suggests,
PKG is a receptor for the second messenger 3’,5’-cyclic guanosine monophosphate
(cGMP). =
Increased levels of intracellular cGMP activate the kinase, thereby triggering
phosphorylation. Within mammalian cells there are three PKG isoforms coded by two
separate genes. The gene prkg1 codes for PKG I which exists as two splice variants PKG
Iα and PKG Iβ (Orstavik et al., 1997). The gene prkg2 codes for the third isoform PKG II
(Gamm et al., 1995).
The expression of these isoforms is tissue specific. The PKG Iα isoform tends to
be expressed in the heart, lungs, cerebellum, and dorsal ganglia regions of the brain
(Hofmann et al., 1992). The PKG Iβ isoform is expressed in the hippocampus and blood
platelets (Geiselhoringer et al., 2004a). The expression of PKG II is widely distributed
throughout the brain (de Vente et al., 2001). PKG is integral in the regulation of neuronal
potentiation, platelet function and smooth muscle relaxation (Hofmann et al., 2006).
1

1.2

The Role of PKG in Smooth Muscle Relaxation
The contraction and relaxation of vascular smooth muscle is a tightly regulated

system that maintains homeostasis throughout the body (Wang et al., 2015). Smooth
muscle contraction is coordinated via calcium influx into the cell triggered by receptor
binding or mechanical stretch stimuli. The influx of calcium results in calmodulin
binding to Ca2+ which interacts with myosin light chain kinase (MLCK) (Kuo et al.,
2015). The now active MLCK phosphorylates myosin light-chain (MLC), activating
myosin ATPase. The activation of myosin ATPase initiates the crossbridge cycle and
causes muscle contraction (Horowitz et al., 1996). Smooth muscle contraction is
inhibited by myosin light-chain phosphatase (MLCP) which dephosphorylates the
myosin (Morgado et al., 2012).
PKG is a key enzyme in smooth muscle relaxation and is the main downstream
effector of nitric oxide (NO) signaling. The NO pathway is initiated by NO production in
the endothelial layer of blood vessels. NO freely diffuses into the adjacent smooth muscle
cells and binds soluble guanylyl cyclase (sGC). Activation of sGC causes the enzyme to
convert guanosine tris-phosphate (GTP) to cGMP (Derbyshire and Marletta, 2009)
(Figure 1.1). The increased levels of cGMP activate PKG which causes smooth muscle
relaxation in several ways but mainly through a decrease in intracellular Ca2+ (Hofmann,
2005). Alterations of intracellular Ca2+ via PKG is achieved in a few ways. The first
mechanism decreases intracellular Ca2+ through the phosphorylation of inositol
triphosphate receptor-associated cGMP kinase substrate (IRAG), this forms a complex
with the inositol triphosphate receptor (IP3R) which inhibits the flow of Ca2+ from the
sarcoplasmic reticulum (SR) (Casteel et al., 2008). Another substrate for PKG that
decreases intracellular Ca2+ is RGS2 (regulator of G-protein signaling 2), this is an
indirect action because phosphorylation of RGS2 results in a decrease of G-protein based
2

IP3 synthesis (Kehrl et al., 2002). The decrease in IP3 reduces the activation of the IP3
receptor and therefore Ca2+ release (Sun et al., 2005). Phospholamban (PLN) is also
phosphorylated by PKG, when PLN is phosphorylated it stops the inhibiting the SR Ca2+ATPase (SERCA) and allows it to pump Ca2+ to the SR, decreasing the level of
intracellular calcium (Lalli et al., 1999).
PKG can phosphorylate Kca 1.1 channel causing a efflux of K+ ions and cellular
hyperpolarization which inhibits the L-type Ca2+ channels from increasing intracellular
calcium levels (Bolotina et al., 1994). Activation of PKG also effects phosphorylation of
myosin in a more direct manner by enhancing the function of MLCP through inhibition
of Ras homolog gene family member A (RhoA) and activation of Myosin phosphatase
target subunit 1 (MYPT1). The phosphorylation of MYPT1 directly causes MLCP
dephosphorylation of the myosin head (Wooldridge et al., 2004). Phosphorylation of
RhoA inhibits the activating of an effector protein that phosphorylates the targeting
region of MYPT1 that would inhibit binding to myosin and dephosphorylation. (Shin et
al., 2002)

3

Figure 1.1. PKG’s role in vascular smooth muscle relaxation.
The vascular smooth muscle signaling pathways controlled by PKG displayed in a
simplified manner. The direct activations are depicted by solid lines and arrows, and the
direct inhibitions are depicted by solid lines with solid perpendicular lines. The indirect
actions are depicted by dotted lines. Abbreviations; soluble guanylyl cyclase: sGC,
Phosphodiesterase 5: PDE5, Regulator of G-protein signaling 2: RGS2, inositol
triphosphate receptor-associated cGMP-kinase substrate: IRAG, Phospholamban: PLN,
Ras homolog gene family member A: RohA, Myosin Light Chain Kinase and
Phosphorylase: MLCK and MLCP, Calcium Activated Potasium channel: BKCa.
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1.3

The Architecture of cGMP- Dependent Protein Kinase Type I
The general organization of PKG’s domains is conserved amongst all isoform.

PKG exists as a parallel homodimer (Huggins et at., 1994). PKG 1α and PKG 1β consists
of 671 and 686 amino acids, with molecular weights of 153 kDa and 156 kDa respectively
(Wernet er al., 1989). These isoforms share sequence homology in their regulatory and
catalytic domains and vary in their dimerization and autoinhibitory domains which has
been shown to affect their activation and substrate targeting (Orstavik et al., 1992, 1997;
Casteel et al., 2010; Qin et al., 2015; Ruth et al., 1991). Located at the N-terminus of the
protein is a dimerization domain (DD) connecting the two protomers together, followed
by a linker region. After the linker region there is an autoinhibitory domain (AI) (aa 187) connected to another linker region. The next domain is the cyclic nucleotide binding
domain, consisting of two cGMP binding sites denoted as the high-affinity A-site (aa 87211) and the low affinity B-site (aa 211-329). At the C-terminus of the B-site there is a
region called the switch helix domain (SW) (aa 329-355) which interacts with the
opposing protomer. Proceeding the SW is the catalytic domain (aa 358-671) (Figure
1.2).

5

Figure 1.2. PKG Iα/Iβ Holoenzyme Domain Organization
Organization of the individual domains within the parallel homodimer of PKG Iα and Iβ.
The dimerization domain (DD), auto-inhibitory domain (AI), High-affinity cGMP
binding site (A-site), low-affinity cGMP binding site (B-site), switch helix (SW), and
catalytic domain sub devided into the ATP and substrate binding regions.

6

1.4

N-terminal Dimerization Domain
The N-terminus of PKG is home to the dimerization domain (DD) which contains

a leucine zipper motif. The leucine zipper is an amphipathic, left-handed α-helix of two
opposing protomers that interact and joins them together (Atkinson et al., 1991; Casteel
et al., 2010; Qin et al., 2015). The helixes in this motif exhibit an amino acid heptad
repeat (abcdefg) with hydrophobic residues at the a and d positions and hydrophilic
residues at the e and g positions (O’Shea et al., 1991; Atkinson et al., 1991). The a
positioned amino acid residues are either leucines or isoleucines, the d position can have
a wider diversity of amino acids. In PKG 1α there are four d residues that are nonhydrophobic amino acids (Phe7, Lys14, Lsy28, Cys42) (Qin et al., 2015). The Cys42
residue is an integral residue in dimerization because it forms a disulfide bond with the
opposing protomer (Monken and Gill, 1980; Schnell et al., 2005)(Figure 1.3.). The
differences in the amino acid sequence in the leucine zipper of different isoforms results
in alternate charge distribution, this causes them to target different substrates
(Schlossman and Desch, 2009). This isoform specific leucine zipper sequence variation
also results in determining their cellular localization via interaction with specific GKinase-anchoring proteins (GKAPs) (Casteel et al., 2008).

7

Figure 1.3. Disulfide bond at cysteine 42 of PKG Iα’s leucine zipper motif
(PBD 4R4L)
Leucine zipper interaction between two opposing protomers of PKG Iα. Highlighted is
the cysteine 42 residue of both protomers which displays the disulfide bond formed
between the two when the protein is dimerized.
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1.5

Autoinhibitory Domain
Following the dimerization domain is the auto inhibitory domain (AI) of PKG.

The AI is found at amino acid 51-68 and 66-83 in the 1α and 1β isoforms, respectively.
This region of the enzyme has been determined to be an important part of PKG
activation. In its inactive form the AI acts as a pseudo substrate for the catalytic domain
causing PKG to adopt a tightly inhibited confirmation (Francis et al., 1996). The AI
residues responsible for this autoinhibition are a glycine at residue 62 in PKG 1α and an
alanine at residue 77 in PKG 1β found in the sequence XISAEP (Kemp et al., 1988;
Francis et al., 1996). The precise mechanism of this inhibition has remained elusive, but
it is most likely through the binding of the phosphate acceptor site of the catalytic region
preventing substrate phosphorylation, a mechanism closely homologous to PKA (Francis
et al.,1996). This inhibition mechanism is supported by the generation of a PKG Iα
mutant with a truncation mutation to Arg77, the resulting enzyme was constitutively
active (Heil et al., 1987; Landgraf et al., 1990; Scholten et al., 2007). Within the AI it has
also been seen that autophosphorylation can occur in the presence of both cAMP and
cGMP at Thr58, this is believed to cause ubiquitination and turnover of PKG Iα (Takioe
et al., 1983; Atiken et al., 1984; Dey et al., 2009).

1.6

Cyclic Nucleotide Binding Domain
The cyclic nucleotide binding domain of PKG is responsible for regulating the

activity of the enzyme. This domain in both PKG Iα and Iβ is structurally identical
containing two consecutive cyclic nucleotide binding sites per protomer. Despite having
the same structure PKG Iα and PKG Iβ have different activation kinetics. It has been
shown that there is a 10-20 fold difference in their cGMP activation constants (Ka), PKG
9

Iα has a Ka of about 100 nM, whereas PKG Iβ has a Ka of 1-2 µM (Ruth et al., 1991). This
variance in activation kinetics is, thought to stem from the differences found in the
dimerization domain (DD) and the autoinhibitory domain (AI) as well (Ruth et al., 1997).
Within this domain the two cGMP binding sites have very different kinetics. The
A-site is known as the high-affinity binding site and binds cGMP with a higher affinity
than the B-site (low-affinity binding site) with binding affinities of 17 nM and 100150nM cGMP, respectively (Corbin et al., 1986). The amino acid residues responsible for
binding cGMP are highly conserved so it is interesting that these two sites display
different binding kinetics for cGMP. The difference may be a result of the theory of the
B-site acting more as a selectivity filter for cGMP. It was initially thought that the
selectivity filter for cGMP over cAMP was a threonine found in both sites in both
isoforms Thr177/192 and Thr301/316 PKG Iα and Iβ respectively (Kim et al., 2011). After
further investigation of an isolated A-site it was determined that the binding constants
(KD) were 12 and 27 nM for cGMP and cAMP respectively showing that there is poor
selectivity via the previous mechanism. It was demonstrated that the cyclic nucleotide
selectivity is caused by the B-site at Arg281/296 which interact with O6 and N7 on the
guanine, in the A-site the equivalent residue is Leu155/170 (Huang et al., 2014; Kim et
al., 2011, 2016).
The holoenzyme crystal structure has yet to be solved, we only have crystal
structures of isolated DD and regulatory domain and therefore do not have a structure
detailing the complex interaction of the cyclic nucleotide binding sites, the N-terminal
domains and the catalytic domain.

10

Figure 1.4

The Regulatory Domain of PKG Iα (PDB 3SHR)

Displayed above is the regulatory domain of PKG Iα consisting of amino acids 77-326.
The domain is split into the high affinity cGMP binding A-site and the low affinity cGMP
binding B-site.
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1.7

The Catalytic Domain
The C-terminal domain of PKG is its catalytic domain (PKG 1α aa 360-671, PKG

1β aa 375-686) responsible for binding substrate/ATP and catalyzing the
phosphorylation reaction. Like all AGC kinases PKG transfers the γ-phosphate of ATP to
a serine or threonine residue of the basic substrate (Alessi et al., 1996). Due to the lack of
complete crystal structures of PKG the exact 3D conformation of this region is unknown.
Therefore, we rely on biochemical data and the known structures of PKA and its
sequence homology models of PKG. The crystal structures of 14 different AGC kinases
show a conserved fold in this domain (Pearce et al., 2012; Taylor et al., 2005). The fold as
seen in PKA show the catalytic subunit is divided into a small N-terminal lobe (N-lobe),
responsible for binding ATP, and a large C-terminal lobe (C-lobe), containing the
catalytic and the substrate binding region (Kim et al., 2007)(Figure 1.5). Within the Nlobe there is a loop containing several glycine residues that bind the Mg2+ binding loop
and ATP. This region arranges the ATPs γ-phosphate into the catalytic site for the
phosphoryl transfer reaction. The N-lobe also functions to help create the active site by
coordinating components of the C-lobe. The C-lobe is responsible for a majority of the
reaction catalyzing residues. The C-lobe contains a catalytic loop containing an aspartate
which deprotonates the substrates serine or threonine residue. Mg2+ ions are positioned
via N-lobe residues and the activation loops DFG motif. A threonine residue (Thr197) in
the activation loop is phosphorylated causing a conformational change aligning the Nlobe, the activation loop and substrate binding sites to their active positions (Bastidas et
al., 2013; Smith et al., 1999; Steichen et al., 2012). It has been shown that Thr516 on PKG
Iα serves as the equivalent to Thr197 of PKA (Feil et al., 1995). The lack of PKG
holoenzyme crystal structure leaves some uncertainty about the structural details of its

12

catalytic domain but sequence homology with PKA allows us to make well educated
assumptions that suggest it functions much like the mechanisms above.

13

Figure 1.5. Catalytic domain of PKA
Displayed is the catalytic domain of PKA which is structurally homologous to all AGC
kinases and therefore is relevant as a model for the catalytic domain of PKG. The model
displays the N-lobe and C-lobe of the domain top and bottom respectively. The
catalytically relevant loops are color coded. The red loop represents the glycine rich loop.
The yellow loop represents the catalytic loop. The orange loop represents the activation
loop. The magenta loop represents the P + 1 loop. Within the N-loop are two Mg2+ ions
and bound ATP, blue and salmon respectively.
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1.8

The Switch Helix
Directly following the B-site a domain known as the switch helix (SW) was

discovered through x-ray crystallography by Osborne et al. (2011) (Figure 1.4). The SW
is an α-helix located at the junction of the regulatory and catalytic domains, amino acids
329-355 of PKG Iα. The C-terminus of the helical switch domain consists of a series of
hydrophobic residues (AAFFANL) called the “knob” (aa 350-345) which interacts with
complementary hydrophobic residues of the phosphate binding cassette (PBC), the N3A,
αB and β6 motifs from the B-site of the opposing protomer, this is called the “nest”
(Osborne et al., 2011; Moon et al., 2013). Including the leucine zipper of the DD this SW
domain represents one of only two sites of interprotomer interaction and
communication.
The effect of the switch helix on PKG activation was explored further by Moon et
al. (2015) who found that a synthetic peptide of the same sequence of the alpha helix
from the SW (aa 329-358) known as S-tide 1.1 (S1.1) activated PKG 1α independently of
cGMP (Table 1.1). Following this discovery, a series of synthetic S-tides were created to
determine the essential amino acid sequence for activation. The C-terminal amino acids
were analyzed for significance, removing 3 amino acids at a time two S-tides were
created and showed that the first three could be removed without change in activity
(S1.2), however the subsequent deletion (S1.3) resulted in an inactive peptide due to the
absence of the knob residues. The N-terminus was then investigated in the same manner
resulting in two S-tides with 3 and 6 amino acids removed S1.4 and S1.5 respectively. The
truncations resulted in increased activity with as low as 3 µM S1.5 (Moon et al., 2015).
This effect is only observed in PKG Iα and not PKG Iβ and presents the possibility of a
PKG Iα selective novel drug target.
15

A

B

Figure 1.6. Switch helix domain of PKG Iα (PDB 3SHR)
Pictured is the switch helix domain of PKG Iα as well as the cGMP A & B site of the
regulatory domain. The two opposing protomers are denoted by green and purple and
the various subparts of each domain are labeled with red arrows. A; represents one
protomer of the SW and regulatory domain whereas B represents the interaction of the
two opposing protomers

16

Table 1.1. S-Tide Name and sequence.
The name of the sequences are listed in order of development on the left of the table
followed by their corresponding sequences, activation constant (Ka) in µM concentration,
and Hill coefficient (nH). The peptide sequences are aligned based on the position of the
knob sequence.
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1.9

Aims of Thesis
The following central hypothesis and specific aims were constructed to explore

the structure activity relationship of S-tide mediated activation with respect to the cGMP
B-site.
Hypothesis: The binding site for the S-tides (nest) and the cGMP
binding site B interact and are co-dependent of one another.
Aim 1: To develop an S1.5 analog that utilizes both the nest and the Bsite to increase S-tide activity.
To test this, we will create two peptides derivatives of S1.5 with sequential Cterminal modifications to probe the low affinity cGMP B-site. The first of the two
peptides will be a three amino acid truncation that is necessary for further peptide
modification. The second will consist of the truncated peptide with the addition of a
cysteamine linker that should reach the B-site. The activity of these peptides will be
tested via kinase assays.
Aim 2: To explore the intricacies of cGMP and S-Tide mediated
activation and how they interact with each other to obtain a better
understanding of the interplay between these two sites.
To test this, we will use of activator combination kinase assays and mutant forms
of PKG allowing us to create a kinetics based model of the activation of each of these
sites. The combination assays will consist of a constant concentration of cGMP with dose
response concentrations of S1.5 and constant concentration of S1.5 with dose response
concentrations of cGMP. To test the direct effect of the B-site interaction with the SW we
will be testing the B-site knock out mutant (E292A). To test the overall similarity in
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activation mechanism we will employ the C42S mutant which has a documented
degradation of cGMP activation.
The aim of this thesis serves to explore the structure to function relationship of
the switch helix domain of PKG. The previous work of the Dostmann laboratory
uncovered the structure of the switch helix domain and went further to discover the
unique ability of synthetic peptides, derived from the switch helix, to activate the
holoenzyme and establish the possibility for a novel drug target not before observed.
This preliminary work warranted further exploration into the mechanics of this unique
property of PKG. It was necessary to test the effects preincubation had on S-tide
activation and PKG with cGMP due to the slow binding kinetics of S1.5 and the need to
establish standard assay conditions. To further explore the possibilities of S-tides new
derivatives of the most potent S-tide (S1.5) were created via molecular modeling with the
rational of creating a peptide that would interact with the adjacent cGMP B-site of PKG
Iα. The possible interaction would strengthen the activation kinetics of the S-tides. This
portion of the thesis demanded that we construct intermediary S1.5 analogs to test the
kinetic effect of removing the three c-terminal amino acids of S1.5 and the addition of a
linker resulting in the new S2.5 and S3.5 peptides. To test their role, we employed
secondary structure analysis via, circular dichroism spectroscopy, as well as kinetic
assays. We hypothesized that the subtraction of these amino acids would not have a
significant effect and if they did it would be due to a loss of helicity.
Since the switch helix binding site shares amino acids with the phosphate binding
cassette (PBC), the N3A, αB and β6 motifs from the B-site prompted us to investigate the
interplay between cGMP and S-tide activation. We hypothesized that the mechanism of
activation was linked. To test this, we employed activator combination assays with PKG
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Iα WT as well as the mutant PKG Iα E292A (B-site knock-out). To test the similarity of
the two forms of activation we employed the mutant PKG Iα C42S which has
documented degradation of cGMP activation. This work was conducted to further our
understanding of the switch helix and its mechanism of action. The results of this
endeavor serve as a base for further research into the structure and function of PKG and
its exploitation as a potential novel drug target.
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2.0

MATERIALS AND METHODS

2.1

Protein Expression and Purification

2.1.1 Blue-White Screening
Expression of recombinant wild type and mutant bovine PKG Iα was
accomplished using the insect cell (Sf9) Bac to Bac baculovirus expression system
(Invitrogen). First the cDNA coding for the PKG variants was transposed from pFAST
Bac HTA into bacmid. Approximately 50 ng of the pFAST Bac HTA containing the
construct was added to chemically competent DH10 Bac E.coli cells. The cells were heat
shocked at 42⁰ C for 30 seconds to allow the plasmid to enter the cells. 100 µL of Luria
medium (Luria-Bertani or LB) was added and incubated at 37⁰C for 5 hours in the
shaker at 220 rpm. KGTIX plates were prepared with LB agar; 50 µg/mL kanamycin;
7µg/mL gentamicin; 10µg/mL tetracycline; 40 µg/mL isopropyl β-D-1thiogalactopyranoside (IPTG), and 2.4 mg of X-gal (on the surface). The E. coli were
plated on a KGTIX plate and incubated at 37⁰C for 24 hours, followed by 4⁰C incubation
to develop blue or white color depending on disruption of LacZ gene. Typically, white
colonies were picked and re-streaked onto two separate KGTIX plates. This procedure
was repeated until well separated single white colonies could be harvested for bacmid
isolation.

2.1.2 Bacmid Isolation
Following blue-white screening, the Bacmid DNA was harvested from a single
colony that was expressing the white phenotype which meant the gene was transposed
into the gene that codes for β-galactosidase which would normally break down the
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galactose from the plate and turn the colony blue. A white colony from each re-streak
was harvested and suspended in 6 mL of LB containing 50 µg/ mL kanamycin and 7 µg/
mL gentamicin. The colonies were grown for 16 hours at 37⁰C and 220 rpm in the shake
incubator. The tubes were centrifuged at 3000xg for 5 minutes, the supernatant was
discarded, and the resulting pellet was resuspended in 300 µL of Quiagen Buffer P1 (50
mM Tris-HCL, 10 mM EDTA, 50-100 µg/ mL RNase A, pH 8.0). The solution was
transferred to a 1.5 mL Eppendorf tube, 250 µL of Quiagen Buffer P2 (200mM NaOH,
1% SDS and LyseBlue indicator) was added and if lysis occurred the solution would turn
blue. 350µL of Quaigen Buffer N3 (4.2 M guanidine hydrochloride (GuHCL), 0.9 M
potassium acetate, pH 4.8) was added. The tubes were then centrifuged for 20 minutes
at 15,000xg to remove cellular debris, the supernatant was transferred to a 2 mL tube
with 800µL of 100% isopropanol, the solution was mixed via inversion, and the tubes
were stored at -20⁰C for up to a month. The samples were then centrifuged at 15,000xg
at 4⁰C for 30 minutes. The supernatant was decanted, and 7 washes were conducted to
remove any remaining salt by adding 1mL of ice cold 70% ethanol to each tube and
incubated for 10 minutes at 4⁰C, followed by 15,000xg centrifugation at 4⁰C for 10
minutes. The supernatant was then decanted, and the pellet was air dried. The pellet was
rehydrated with 200 µL of sterile ddH2O and stored overnight at 4⁰C. The concentration
was determined by Nanodrop® spectrophotometry 260/280 nm and corrected to 500
ng/µL.

2.1.3 M13 PCR Bacmid Analysis
Following bacmid isolation, it was necessary to determine if the gene of interest
was inserted into the E.coli, M13 PCR was employed for this determination. Each PCR
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reaction had a total volume of 50 uL containing 150 ng of the bacmid, DreamTaq,
200nM M13 forward primer (CCCAGTCACGACGTTGTAAAACG), 200nM M13 reverse
primer (AGCGGATAACAATTTCACACAGG), and ddH2O. The reactions were mixed and
then run in the thermocycler with temperatures and times determined based on the
primers and the DreamTaq DNA polymerase (Fisher scientific) (Table. 3.1). Following
the PCR, a 1% agarose DNA gel (Ultrapure agarose by Invitrogen) containing SYBR Safe
stain (Thermo scientific) was run with 20 µL of each reaction and 5 µL of a 1Kb DNA
ladder (BioLabs). The gel was run in the dark in order to preserve the florescent dye at
100 volts for 45 minutes. the resulting band was the ladder equivalent of 2430 base pairs
+ the inserted genes length, approximately 2,013 base pairs for PKG Iα.

step Stage

temperature

Time (min)

1

Hot start

95⁰C

1:30

2

Denature

95⁰C

0:45

3

Annealing

50⁰C

0:45

4

Extension

68⁰C

5:00

5

Cycle

To stage 2, repeat 30x -

6

Final extension 68⁰C

7:00

7

Storage

Forever

4⁰C

Table 2.1. M13 PCR run table
The sequence of events during M13 PCR with the corresponding temperatures and times.
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2.1.4 Transfection and First Amplification of Baculovirus
Once it was determined that the gene of interest was inserted into bacmid, Sf9
cells were transfected to produce baculovirus. Under sterile conditions, 2 mL of Sf9 cells
at a concentration of 0.5 x 106 cells/mL in unsupplemented Sf900 III medium (Thermo
scientific) were added to each well of a 6 well plate. The cells were allowed to adhere for
30 minutes, followed by a media change with new unsupplemented Sf900 III medium
(Thermo scientific). The plate was constructed with a duplicate series of the
experimental conditions; control (0 µg), 1 µg, and 2 µg of a single Bacmid. Tubes were
prepared for each set of wells with 300 µL of unsuplemented Sf900 III medium and their
varying concentrations of bacmid as well as 6 µL of Cellfectin (Invitrogen). 200 µL of the
corresponding bacmid solutions were added to each well dropwise. The plate was
incubated for 5 hours at room temperature, followed by a media change with Sf900 III
medium (Thermo scientific) containing 10 µg/mL gentamicin (Sigma-Aldrich), 0.01%
poloxamer-81 (Sigma-Aldrich), and 1x lipids (Sigma-Aldrich). The plate was then
incubated at 27⁰C and assessed every day after to determine if the cells were transfected.
Once the cells reached late stage infection, the cells were scraped off the bottom of the
wells and the duplicate wells were pooled. The cell samples were centrifuged at 500 x g
for 5 minutes. The supernatant containing the virus was transferred to a dark conical and
stored at 4⁰C until subsequent steps.

2.1.5 Second Amplification of Baculovirus
To increase the viral titer, a second amplification was needed. 25 mL of Sf9 cells
at a concentration of 1 x 106 cells/ mL were added to a 75 cm2 tissue culture flask and
were allowed to adhere for 1 hour. 200 µL of the first amplification baculovirus were
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added to the flask and incubated at 27⁰C until they reached late stage infection. The cells
were collected and centrifuged at 500 x g and 4⁰C for 5 minutes. The supernatant was
collected in a dark 15 mL conical, as with the first amplification virus, and then stored at
4⁰C.

2.1.6 Third Amplification of Baculovirus and Test Expression
A third amplification was performed to further increase the viral titer and a test
expression was performed to determine the resulting potency of the virus. 40 mL of Sf9
cells at a concentration of 1 x 106 cells/ mL and 2.5 mL of second amplification virus
were added to a 125 mL baffled flask. They were incubated at 27⁰C and 80 rpm until they
were in late stage infection. The cells were then harvested, centrifuged at 500 x g for 5
minutes and the supernatant was transferred to a dark conical and stored at 4⁰C. To test
the potency of the resulting baculoviral a test expression was performed with varying
concentrations of virus and the resulting samples were subjected to a western blot to
determine the titer and optimal infection conditions.
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2.1.7 Expression and Purification of PKG Iα
Once the viral titer was determined, a full expression of PKG Iα and subsequent
purification were performed. To a 2.8 L baffled flask, 1 L of Sf9 cells was added at the
concentration of 1.5 x 106 cells/mL in Sf 900 III media (Thermo scientific). Baculovirus
was then added from the third amplification at a volume of (1/500)*volume of cells. The
cells were incubated at 27⁰C and 80 rpm for three days. The cells were then harvested,
centrifuged at 500 x g for 30 minutes and the supernatant was discarded. 1 mL of a 10x
protease inhibitor cocktail was added to the pellet to inhibit proteolysis of PKG. 20 mL of
cold lysis buffer (10 mM TES Ph 7, 300 mM NaCL, 5mM imidazole) were added to resuspend the pellet, and the cells were lysed. The lysate was then centrifuged at 25-40K x
g (15K RPM Sorvall SS-34 rotor) for 90 minutes at 4⁰C. While the lysate was centrifuged,
a nickel affinity chromatography column was regenerated with the rational of (Table
2.2). The lysate was loaded onto the column and the flow through was collected for each
of the subsequent steps. The first wash was performed by running 7 column volumes
(CV) of lysis buffer through the column. A second wash was then performed with 5 CV of
mid wash buffer (10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole). Once washed, an
elution was performed by running the elution buffer (5 mM TES Ph 7, 300mM NaCl, and
250 mM imidazole) through the column; five 5 mL fractions were collected. Qualitative
analysis via Bradford assay was performed by combining 20 µL of each fraction with 1
mL of 1x Bradford reagent and the color was noted; blue indicated the presence of
protein. Once the fractions containing the protein were identified, they were pooled. The
pooled fractions were dialyzed in 2 L of dialysis buffer twice (50 mM MES Ph 6.9, 300
mM NaCl, and 1mM Tcep) at 4⁰C overnight on a stir plate to exchange the buffer. A third
dialysis was performed to exchange the buffer to the final storage buffer (50 mM MES ph
6.9, 150 mM NaCl, 1 mM TCEP, and 10% glycerol). The resulting protein concentration
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was determined via Nanodrop® spectrophotometry (Fischer scientific) at λ=280 nm
with the molar coefficient of 81,250, determined by the ProtParam tool (ExPASy).
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Solution

Volume

Concentration

(CV)
EDTA

10

50 mM

ddH2O

2

NaCl

1

ddH2O

2

NaOH

1

ddH2O

10

NiSO4

4

1M

Equilibration

5

50 mM NaOAc, 300 mM NaCl

1M

1M

Buffer
ddH2O

10

Lysis buffer

5

10 mM TES Ph 7, 300 mM NaCL, 5mM imidazole

Wash buffer 1

7

10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole

Wash buffer 2

5

10 mM TES Ph 7, 300 mM NaCl, 3mM imidazole

Elution buffer

6

(5 mM TES Ph 7, 300mM NaCl, and 250 mM

Cell lysate

imidazole

Table 2.2. Nickle affinity chromatography regeneration and purification
The sequence of events when regenerating the nickel chromatography column and
purification of cellular lysate. The regeneration consists of the first 10 steps and the
purification is the remaining 4 steps. At the elution, six 5mL fractions are collected.
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2.2

Peptide Synthesis
The synthetic peptides (S-tides) were synthesized via solid-phase synthesis on

Rapp S RAM resin (Rapp Polymere) with a Syro multiple peptides synthesizer
(MultiSynTech) by Werner Tegge (Helmholtz Center for Infectious Research). Fmoc
solid-phase synthesis was employed with tenfold excess of 2-(1H-Benzotriazole-1-yl)1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) and diisopropylethyl amine
activation. The coupling reaction was performed for 1 hour. The amino acid sidechains
were protected with the following rational: Asp, Glu, Ser, Thr and Tyr: with a tert-butyl
group; Asn, Cys, Gln, and His: with a Trityl group; Arg with a 2,2,4,6,7Pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) group; lys and Trp: with a tertButyloxycarbonyl group. The resulting peptides were cleaved off the Rapp S RAM resin
and the protecting groups were removed with a solution of Trifluoroacetic acid (TFA),
3% triisopropylsilane and 2% water. The peptides were purified via high-performance
liquid chromatography (HPLC) and then lyophilized to removing any remaining water.

2.3

Circular Dichroism Spectroscopy
To determine the secondary structure of the S1.5 and S2.5 peptides, we employed

circular dichroism spectroscopy with the help of Werner Tegge (Helmholtz Center for
Infectious Research). The circular dichroism (CD) spectra of S1.5 and S2.5 were
measured with a JASCO J-815 circular dichroism spectrometer at 20⁰C with a cell
thickness of 0.5 mm. Each sample measured contained 100 µM peptide in 50 mM
sodium phosphate pH 7.0. The samples were scanned at 50 nM / min with a range of
190-300 nM. for each wavelength. 10 replicate scans were performed which were
averaged for the resulting spectra of each peptide.
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2.4

P81 Phosphotransfer-Assay
To test the kinase activity of the purified PKG and the various experimental

conditions, a radioactive assay was adapted from the work of (Landgraf and Hofmann.,
1989) as well as (Dostmann et al., 1999). In this assay PKG performs a
phosphotransferase reaction which transfers the terminal phosphate of a P 32 tagged ATP
molecule to the basic W15 peptide substrate that has the amino acid sequence
TQAKRKKSLAMA (Dostmann et al., 1999). The reaction is transferred to a Whatman
P81 phosphocellulose filter paper which binds the substrate and allows for accurate
measurement of CPM in a liquid scintillation counter. Based on the degree of
radioactivity, the velocity at which the kinase phosphorylates the substrate can be
determined. Using a series of increasing concentrations of activator in each reaction we
are able to plot the resulting velocities and determine the kinetic profile of different
conditions and activators with respect to PKG.
To prepare for the kinase assay, the reactions were labeled and organized in
duplicate 1.5 mL Eppendorf tubes with blank, zero and the varying concentrations of
cGMP. 10 µL of each 10x cGMP stock was aliquoted into their respective tubes and
DDH2O in the blank and zero. The reaction tubes were stored at 4⁰C until it was time to
run the reaction. The Whatman P81 phosphocellulose filters (2cm/1.9cm) were labeled
to their corresponding reaction number. For each reaction, 20 µL of 5xMES mix (250
mM MES ph 6.9, 5mM MgoAC, and 50mM NaCl), 10 µL of 100 mM DTT, 10 µL of 10
mg/mL BSA (Cohn’s fraction V), 10 µL of 100 µM W15 substrate, and 10 µL of DDH2O
were added to a 15 mL conical on ice constituting the batch reaction mix. Prior to adding
the ATP to the reaction mix, it had to be spiked with P32 tagged ATP.
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To determine the specific activity of the P32 tagged ATP, 10 µL of 1mM for each
reaction plus 50 µL was added to an separate tube then P32 tagged ATP was added with
the rational that 1/100 * total volume (ATP) = volume P32 ATP added on the 1st day of
receiving it and 1/50th at 1 half-life (14 days). Once the ATP was spiked 5 µL was diluted
1:10 and then in duplicate 10 µL was blotted onto P81 filter papers and then measured in
the liquid scintillation counter. Once the specific activity of the ATP was determined, 10
µL for each reaction was added to the reaction mix. 70 µL of the reaction mix was added
to each reaction tube. The reactions are activated with the addition of 20 µL of diluted
PKG.
A dilution of the PKG stock was created in Enzyme Dilution Buffer (EDB) (50mM
MES ph 6.9, 1 mg/mL BSA (cohn’s fraction V), 1 mM TCEP, and 50 mM NaCl) resulting
in a 10x stock of PKG that corresponds to 8 ng of PKG per reaction ensuring steady state
conditions. The reactions were initiated with 20 µL of the diluted PKG (pipetted 10 times
for consistency), and 20 µL of ddH2O for the blank condition, resulting in a total reaction
volume of 100 µL. The reactions proceeded at 30⁰C for 3 minutes. To terminate the
reaction, 50 µL of the reaction was blotted onto its corresponding Whatmann P81 filter
paper, which was then washed in 20 nM phosphoric acid 4 times to stop non-specific
binding and remove unbound P32. The filters were dried, placed in scinti vials containing
PPO and POPOP in toluene, and their CPM was measured via liquid scintillation counter
(Perkin Elmer).

2.4.1 S1.5 and cGMP Pre-Incubation and S-tide Analog Kinetic Assays
The work of Thomas Moon et al., 2015, established that the binding kinetics for
S1.5 was quite slow and that it required pre-incubation with PKG Iα in order to activate
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it. For this reason, it was necessary to adapt the procedure from section 2.4.0 to allow
for a 30 minute incubation prior to activation. The cGMP and S1.5 kinase assays without
incubation were conducted with the previously stated procedure using the same set of
reagents and timing. The cGMP and S1.5 assays with incubation were performed with the
same reagents and concentrations but differed in the setup and initiation. To allow for a
30 minute incubation of PKG with either S1.5 or cGMP, the 10 µL of the activator and 20
µL of the diluted PKG were added to the reaction tube first and incubated at 30⁰C for 30
minutes. The reactions were initiated with the addition of 70 µL of the reaction mix. The
reactions proceeded for 3 minutes and were terminated as previously stated. This
method of assay was used to perform the assays in which we tested the new S-tide
analogs.

2.4.2 Activator Combination Assays and PKG Iα Mutant Assays
To test the effect of activating PKG Iα with a combination of S1.5 and cGMP, the
procedure specified in section 1.4.1 was altered slightly allowing for pre-incubation and
the addition of another reagent. Like 1.4.1, the activator was combined with the PKG Iα
for a pre-incubation. In this case it contained 20 µL of the PKG dilution, 10 µL of the
cGMP stock and 10 µL of the S1.5 stock. To compensate for the 10 µL of the second
activator, the 10 µL of DDH2O was omitted from the reaction mix. After the 30 minute
incubation, the reactions were initiated with 60 µL of reaction mix. The reactions
proceeded for 3 minutes and were terminated in the same manner previously described.
To test if S1.5 shares the same degradation of activity as cGMP when activating the C42S
mutant, two procedures were used. To establish the kinetics of cGMP on C42S, we
employed the same procedure as 2.4.1. A pre-incubation was needed to activate C42S
39

with S1.5 due to its slow binding kinetics. The E292A mutant was tested in the same
manner as C42S with the addition of a combination assay, as stated previously, to
determine the effect of the B-site knockout.

2.5.0 Synthesis of P81 Phosphocellulose
Our protein kinase assay relies on the use of phosphocellulose paper (P81) as a
means to trap the enzyme’s reaction product, phosphorylated substrate peptide
(Dostmann., 2000). When the maker of P81 discontinued its product line, it became vital
to develop a protocol for the reliable and sustainable synthesis of phosphocellulose. By
utilizing sodium trimetaphosphate (P3m) (Figure 2.5.1) we succeeded to develop a semiautomatic method by converting 10 x 10cm sheets of regular cellulose filter paper
(Whatmann) at PH 12.0 and 50⁰C (Inoue., 1995). P3m reacts with hydroxyl-groups of αD-glucose and other sugars by a nucleophilic substitution reaction to form mostly
monophosphate derivatives. Triphosphate derivatives will also be formed to a lesser
degree. The reaction solution was constantly adjusted to PH 12 by addition of 6M NaOH
solution. To assure equal reaction conditions for all paper sheets, a device was designed
that would hold each sheet in quasi suspension (Figure 2.5.2). The device was 3D
printed in the lab using ABS (Acrylonitrile butadiene styrene) plastic on a PRUSA I3
MK3 printer. A Büchner funnel holding 6M NaOH and a PH electrode allowed for
constant monitoring and addition of NaOH. After a 2 week reaction time, the
phosphocellulose sheets were extensively washed, dried in acetone and subsequently in
air, and cut to size (2x2 cm). A quality test revealed that our P81-paper had similar
capacity and signal stability across all sheets. For this a PKG kinase assay was used under
fully saturated conditions.
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Figure 2.5.1 Structure of Sodium Tirmetaphosphate (P3m)
Above is the structure of the sodium trimetaphosphate (P3m) used in the reaction with
cellulose paper to result in the synthesis of phosphor cellulose.

Figure 2.5.2 P81 Filter Production Device
The figure above is the final design of the filter suspension system. The holder was
designed to fit into a 2 L beaker and produces 16 8x8 filters. The bottom is raised to
allow for a stir bar to move freely.
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2.5.1 Validation of P81 Phosphocellulose
To determine the efficacy of the phospohocellulose produced in 2.5.0 we
employed kinase assays with PKG 1α as described previously using 5 µM cGMP to
achieve maximal activation. In order to test the consistency amongst all filter’s sheets
produced in one synthesis a filter cut from the same location on all sheets were reacted
with the same conditions. To test the consistency across the whole filter sheet, the whole
sheet was divided into equal 2 x 2 cm and they were reacted with consistent conditions.
To overall efficacy of the synthesis the same kinase assay was performed testing our
filters against Whatman P81 filters we had saved for this purpose.
2.6

Data Analysis
In order to interpret the data collected from the various experiments conducted

in this thesis several programs were employed to covert raw experimental data into
usable kinetic information. When the kinase assay is performed we obtain counts per
minute (CMP) from the liquid scintillation counter. This data is imported into excel
where the average velocity minus the blank is calculated of two replicate counts. The
velocity is calculated by multiplying the CMP by the blotting and purity correction and
dividing by the reaction time, concentration of protein and the specific activity. This
results in the velocity (µmol(P-W15) / min x mg (PKG)). The velocities and their
corresponding activator concentrations are then imported into Graphpad Prism™ where
a nonlinear regression curve fit is performed on velocity vs Log concentration to
calculate the kinetic constants KA, nh, Vmax, Vmin and fold activation. The non linear
curve fit generates the accompanying graphs seen throughout this thesis.
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3.0

RESULTS

3.1

Protein Expression and Purification
To explore the objectives of this thesis it was necessary to express and purify

recombinant PKG Iα wild type as well as the various mutant forms of PKG. The Bac to
Bac baculovirus protein expression system (Invitrogen) was employed because bacterial
expression of PKG Iα has yet to be accomplished (Feil et, Al., 1993). Wild type PKG Iα as
well as all typesof mutant forms of PKG expression and purification has been developed
in the Dostmann Lab (Dostmann et,al., 2000; Sheehe., 2018). Likewise the expression
the of the mutant forms of PKG Iα E292A and C42S was performed using this
established protocol.
Following lysis and Ni2+ affinity chromatography, a correlative Bradford assay
was performed on each of the elution samples to determine which fraction contained the
protein (Figure 3.1.1). To further establish purity of the enzyme preparations, gel
electrophoresis using 1mm 4-20% TGX gel, were performed on the clarified lysate (CL),
flow through (FL), first wash (W1), second wash (W2), elution 3 (E3), and elution 4 (E4)
(Figure 3.1.2.). From the pooled and dialyzed fractions, the concentrations and total
yields were determined (Figure 3.1.3). Lastly, to determine if the resulting PKG Iα
enzymes were pure and functional, a Kinase assay was performed on wild type with
varying concentrations from 2 nM – 10 µM of cGMP. The resulting data was subjected to
a non linear regression curve fit to determine the kinetic characteristic of the enzyme
(Figure 3.1.4., Table 3.1.1). The total yields for the expressions for PKG Iα WT,
E292A, and C42S were 14.2 mg, 5.4 mg, and 10 mg, respectively. The resulting activity
with cGMP was consistent with previously determined data.
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Figure 3.1.1. Correlative Bradford analysis of PKG Iα WT purification
Fractions.
This figure displays the results of combining 5 µL of elution fraction to 1 mL of Bradford
reagent. The analysis is sequentially elution fractions 1-6. The color change is dependent
of the presence of protein from changing from brown to blue when protein is added.

Figure 3.1.2. Gel electrophoresis of PKG Iα WT purification steps.
The gel above is the result of running 15 µL of sample from each step of the Ni affinity
chromatography performed on the cellular lysate of sf9 cells expressing PKG Iα WT and
5 µL of protein ladder on a 1mm 4-20% TGX protein gel for 30 minutes at 190 V and
0.68A. From left to right the columns were as follows; protein ladder, clarified lysate
(CL), flow through (FL), wash 1 (W1), wash 2 (W2), ladder, elution 3 (E3), and elution 4
(E4).
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Figure 3.1.3. Test activation of PKG Iα wild type prep with cGMP.
Above is a nonlinear regression curve fit of cGMP activated PKG Iα WT (N=2). The curve
was created with individual reaction velocity’s from 9.3 ng of PKG Iα, varying
concentrations of cGMP 2nM – 10 µM and reaction times of 3 minutes. The x-axis
displays the log concentration of cGMP and the Y-axis is the reaction velocity in µ mols
of phosphorylated w15 substrate per minute mg of PKG Iα.

cGMP
7.6 ± 0.05
0.34 ± 0.044
22.4
1.58 ± 0.06
0.13 ± 0.064

Vmax (µmol x min-1 x mg-1)
Vmin (µmol x min-1 x mg-1)
Fold Activation
nh
Ka (µM)

Table 3.1.1. Kinetic constants derived from the non linear regression fit of
the cGMP PKG Iα activation curve.
Displayed are the kinetic variables determined from the kinetic analysis in Figure x.
The experimental conditions are listed in the top row and their corresponding kinetics
are in their respective columns. Vmax corresponds the maximal velocity of each curve, nh
corresponds to the hill coefficient of the curve, and the Ka is the activation constant of
each curve.
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3.2
Determination of optimal Activation Conditions for S-tide Activation
of PKG-Iα
The work of Moon et al. (2015) explored the idea of synthetic peptides activators
of PKG Iα derived from the recently discovered switch helix domain and determined the
S1.5 peptide (YEDAEAKAYEAEAAFANLKLSD) to be the most active. While studying the
peptides binding kinetics it was discovered that it required extended incubation with
PKG Iα to reach maximal binding. This determines the need for a preincubation of the Stides with PKG prior to kinetic analysis. This addition to the established P81 phosphoryl
transfer assay warranted experimentation to determine the effect that preincubation has
on PKG Iα wt so that the S1.5 analysis can be deemed valid. It was hypothesized that an
incubation of 30 minutes at 30⁰C would result in ample time for S-tide binding and
would not result in any negative effect on the enzyme itself. To test this hypothesis,
kinetic assays were performed on PKG-Iα WT with both cGMP and S1.5 comparing
preincubation and no preincubation. The resulting data by plotting reaction velocity
against the Log concentration of activator with a four-parameter nonlinear regression
curve fit (Graph pad Prism). Below, the combination graph displaying each condition as
well as the table with their respective Vmax, activation constant (Ka), and hill coefficient
(nh) (Figure 3.2.1., Table 3.2.1). This data shows that there is no effect on the
activation profile when the enzyme was activated with cGMP supported by the Vmax of
about 4 µmol(w15-p)/min*mg and a Ka of about 100µM for both trials, which is in
agreement with the published values. Conversely preincubation greatly improved the
activation of S1.5. As for the S1.5 the no preincubation trial resulted in an activation
profile that could not reach maximal velocity at testable concentration, the preincubation
S1.5 resulted in hill coefficient (nh) of 2.5 and activation constant (Ka) of about 6 µM
which is consistent with previous data (Moon., 2015).
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Figure 3.2.1. Activation curves comparing cGMP V.S. S1.5 and preincubation
V.S. no incubation (N=4,2,8,6 respectively).
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator
(cGMP and S1.5). The increasing concentrations were plotted in order resulting in a
sigmoidal curve of PKG-Iα activation.

Vmax
Vmin
Fold
Activation
nh
Ka [µM]

cGMP
Preincubation

cGMP
no
Preincubation

S1.5
Preincubation

S1.5 no
preincubation

4.04 ± 0.022
0.65 ± 0.024
6.2

4.0 ± 0.015
0.44 ± 0.014
9.1

2.31 ± 0.034
0.65 ± 0.041
3.6

-

1.6 ± 0.06
0.11 ± 0.06

1.5 ± 0.031
0.14 ± 0.043

2.5 ± 0.34
5.9 ± 0.72

-

Table 3.2.1. Kinetic constants derived from the activation curves comparing
cGMP V.S. S1.5 and preincubation vs no Pre-incubation.
Displayed are the kinetic variables determined from the kinetic analysis in Figure 3.2.1.
The experimental conditions are listed in the top row and their corresponding kinetics
are in their respective columns. Vmax corresponds the maximal velocity of each curve
[µmol x min-1 x mg-1], nh corresponds to the hill coefficient of the curve, and the Ka is the
activation constant of each curve.
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3.3

Comparing the Activation Kinetics of S-tide Analogs
Following the discovery that the switch helix can activate PKG-Iα, synthetic

peptides were created to explore the necessary amino acid residues for optimal activation
resulting in the S1.5 peptide (see section 3.2.) (Moon et al., 2011, 2015). We worked to
further develop the S-tides and target the adjacent cGMP Bite. As part of this study, it
was concluded that intermediary peptide was needed to test the removal of the L, S, and
D of the S1.5 followed by the addition of a cysteamine linker to increase the binding, the
peptides were named S2.5 and S3.5 respectively (Figure 3.3.1). The hypothesis was that
the removal of the terminal LSD of S1.5 (S2.5) and the addition of the linker (S3.5) would
not alter the kinetics of activation of PKG-Iα. Kinase assays were performed on S1.5, S2.5
and S3.5 and a nonlinear regression curve fit was performed on the resulting data by
plotting the reaction velocity against the logarithm of activator concentration allowing
for calculation of the Vmax, Ka, and nh (Figure 3.3.2., Table 3.3.1). The results of the
S2.5 trials show a significant shift in the activation to the right meaning the activity of
the peptide is decreased from what is seen with S1.5. The S3.5 activation was shifted even
further, meaning it is even less active and that the addition of the linker further degrades
the activity seen in S2.5. when comparing the kinetic constants of all of these S-tides the
degradation of activity is seen with the sequential increase in concentration needed to
reach the Ka; 5.9 µM, 15 µM, and 73 µM for S1.5, S2.5 and S3.5 respectively. A surprising
result from this experiment is that the Vmax from S1.5: 2.3 µmol(w15-p)/min*mg was
severely degraded with the S2.5 modification: 1.6 µmol(w15-p)/min*mg. This
degradation of efficacy seems to be fixed by the addition of the linker in S3.5: 2.7
µmol(w15-p)/min*mg, this points to the need of a protecting group at the end of the Stide. The lack of knowledge of how the holoenzyme is activated warrants further
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exploration. We hypothesized that the removal of the C-terminal LSD could cause helical
instability and prompted secondary structure analysis of the peptide.
It has been determined that the helicity of the S-tides derived from the switch
helix was a crucial factor for activation of PKG Iα (Moon et al., 2015). It was concluded
that shortening of the S-tides via the C-terminus could disrupt the helicity of the peptide
rendering less active. The decrease in activity from S1.5 to S2.5 warranted exploration
into the structure of S2.5 and specifically the helical nature of the peptide which has been
recognized as a critical part of its function. It was hypothesized that helical instability
was the cause of S2.5’s impaired activation kinetics. To test this circular dichroism
spectroscopy was performed on S2.5. S1.5 was used as a control due to its known helical
stability. The secondary structure analysis by circular dichroism spectroscopy results in
different characteristic traces based on the secondary structure of the peptide being
analyzed, an alpha helix will result in a peak at about 190 nm followed by two
consecutive troughs at 205 and 220 nm, a beta sheet will be represented by an initial
peak at about 200 nm and a long sloping trough that terminates at 220 nm, as for a
random coil the trace would show a trough at 200 nm and peak at 220 nm (Bulheller et
al., 2007). The resulting data was graphed, and the two resulting curves were analyzed to
determine the difference in helicity. The helical structure of S2.5 is seen to be almost the
same as S1.5 (Figure 3.3.3), the traces display near identical alpha helix trace
characteristics as mentioned earlier, and therefore doesn’t explain the shift in activation.
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Figure 3.3.1. Structure of S2.5 and S3.5
Displayed above are the structures of the S1.5 analogs S2.5 and S3.5 denoted from N to
C. The N-terminus of these peptides have an acetyl group conjugated onto it protecting
the terminus. The C-terminus of the S2.5 peptide has an amino group attached to protect
the terminus.

Figure 3.3.2. Activation Curves Comparing the Kinetics of S1.5, S2.5, and
S3.5
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator
(S1.5, S2.5, and S3.5). The increasing concentrations were plotted in order resulting in a
sigmoidal curve of PKG-Iα activation with cGMP control at 5 µM.
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Vmax
(µmol x min-1 x mg-1)
Vmin
(µmol x min-1 x mg-1)
Fold Activation
nh
Ka [µM]

S1.5
2.31 ± 0.034

S2.5
1.64 ± 0.021

S3.5
2.8 ± 0.25

0.65 ± 0.041

0.37 ± 0.01

0.49 ± 0.021

3.6
2.5 ± 0.34
5.9 ± 0.73

4.5
3.2 ± 0.22
14.5 ± 0.07

5.8
1.9 ± 0.26
73.1 ± 2.8

Table 3.3.1. Kinetic constants derived from activation curves comparing
S1.5, S2.5, and S3.5 activation of PKG Iα.
Displayed are the kinetic variables determined from the kinetic analysis in Figure
3.3.2. The experimental conditions are listed in the top row and their corresponding
kinetic variables are in their respective columns. Vmax corresponds the maximal velocity
of each curve, nh corresponds to the hill coefficient of the curve, and the Ka is the
activation constant of each curve.

Figure 3.3.3. Circular Dichroism Helical Profile of S1.5 and S2.5
The graph plots mean residue ellipticity (θ) mdeg (y-axis) vs the measured wavelength
(λ) in nm (x-axis). The data points are plotted with increasing measured λ. The difference
line denoted by the triangular points represent the difference between the S1.5 and S2.5
data points.
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3.4 PKG Iα Co-Activation and Activation Site Interplay.
Our original hypothesis on the mode of activation of S-tides and cGMP proposed
a linkage since the SW nest shares residues with the cGMP B-site. However, our findings
from the PKG Iα C42A trials suggest this may not be the case and prompted further
exploration. To further explore the potential interplay between the S1.5 and cGMP
binding sites we studied the kinetics of co-activation between the two. We hypothesized
that co activation would result in a synergistic activation of PKG Iα, if the sites of
activation are linked. To test this hypothesis a series of experiments were devised with
the rational of performing kinetic assays of cGMP and S1.5 but with the addition of half
maximal velocity levels of the other activator. The cGMP assays were performed with
varying cGMP concentrations and a constant concentration of S1.5 at 1 µM. The S1.5
assays were performed with varying S1.5 concentrations and a constant concentration of
cGMP of 100 nM. The resulting data was analyzed by plotting the velocity vs log agonist
concentration with a nonlinear regression curve fit to determine the activation kinetics
(Figure 3.4.1. Table 3.4.1.) The resulting graph shows that the cGMP + 1 µM S1.5 had
little effect on the overall kinetic profile compared to cGMP alone with a slight shift in
the Ka from about 100 nM to about 140 nM. The addition of 100 nM cGMP to S1.5
resulted in extremely high basal activity of about 50% activation which is expected when
using half maximal cGMP. We also saw a shift of Ka from about 5 µM to about 12 µM.
This decrease in potency is contrary to the idea of synergism but when comparing the
Vmax of this trial to S1.5 alone we see that the combination assay resulted in 80%
maximal activation whereas normally we would only see about 60% activation. This
points to the combination causing a decrease in potency but an increase in efficacy. A
potential cause of the decrease in potency could be that the cGMP B-site may not be a
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site of activation but rather a site of regulation for the SW nest site. This idea prompted
us to use more mutant models to explore this possibility even further.
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Figure 3.4.1. Co-Activation curves of cGMP + S1.5 and S1.5 + cGMP. [N=4]
The reported Y-axis units are normalized percentage of maximal velocity of µmols of
phosphorylated substrate (w15-p) per minute mg of PKG-Iα, The S1.5 + cGMP was
calculated from a 5 µM cGMP control run at the end of the data set. The X-axis units are
logarithmic molar concentration of activator (cGMP and S1.5). The cGMP curve, denoted
by the circular data points, had a constant concentration of S1.5 of 1 µM in every
reaction. The S1.5 curve, denoted by the triangular data points, had a constant
concentration of cGMP of 100 nM in every reaction. These curves detail the coactivation
of PKG 1α.
Vmax
(µmol x min-1 x mg-1)
Vmin
(µmol x min-1 x mg-1)
Fold Activation
nh
Ka [µM]

cGMP + 1µ S1.5
100% ± 0.33

S1.5 + 100 nM cGMP
80.38% ± 1.97

12.2% ± 0.29

49.4% ± 1.05

8.2
1.61 ± 0.034
0.14e-7 ± 0.04

1.63
1.9 ± 0.45
12.4 ± 0.34

Table 3.4.1. Kinetic constants derived from the activation curves comparing
co-activation of PKG 1α with S1.5 and cGMP.
Displayed are the kinetic variables determined from the kinetic analysis in Figure
3.6.1. The experimental conditions are listed in the top row and their corresponding
kinetics are in their respective columns. Vmax corresponds the percentage of maximal
cGMP velocity of each curve, nh corresponds to the hill coefficient of the curve, and the
Ka is the association constant of substrate binding for each curve.
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3.5 Activation of PKG Iα E292A mutant with cGMP and S1.5
To elucidate the interaction between S-tide and cGMP activation it was
determined a mutant protein model where the cGMP B-site was knocked out would give
valuable insight into the effect cGMP binding to the B-site has on the activity of S-tides.
The rational for this is that it has been theorized that due to the proximity of the B-site
and the switch helix binding site there is site activation interplay. We wanted to test first
the effect the E292A mutant would have on normal activation via cGMP and S1.5 when
compared to PKG Iα WT. Therefore, we performed kinase assays where E292A was
activated with cGMP and S1.5. Secondly, we wanted to see what the direct interplay
would be if we co-activated the E292A mutant. This experiment is in response to the
results of the experiments were we coactivated PKG Iα WT, it was thought there would
have been synergism but what we saw was the opposite. This lead us to the idea that
cGMP binding to the B-site might be interfering with the switch helix binding site. To
test this, we employed the E292A mutant in a co-activation assay to see if the effect is
rectified by the knockout of the B-site. The assays were conducted with constant
concentration of one of the activators at half maximal concentration and then a full
activation curve of the other activator.
The resulting data was graphed and was subjected to a nonlinear regression curve
fit to determine each conditions kinetics (Figure 3.5.1., Table 3.5.1). When comparing
the kinetics of the cGMP and S1.5 activation of E292A with that of PKG Iα WT (Table
3.5.1.) it is seen that there is no significance change in the kinetic constants. The
combination assay where there was 1 µM S1.5 and varying concentration of cGMP the
resulting activation curve has a slight decrease in Vmax; from 3.021 to 2.56 (µM(W-15
and hill slope potentially. The combination assay in which we had a constant 100 nM
cGMP and varying S1.5 concentration we saw a very high basal activity of about half
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maximal which is consistent to the wild type combination experiments. This experiment
also resulted in a shifted activation in which the Vmax was not able to be reached at the
concentrations we tested and therefore a significant Ka could not be calculated but seems
to be around 100 µM. This also points to a higher Vmax as well pointing to an increase in
activity when compared to S1.5 activating E292A by itself which is consistent to the wild
type combination assays.
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Figure 3.5.1. Co-Activation of PKG Iα E292A with cGMP [N=4], S1.5 [N=4],
cGMP + S1.5 [N=2] and S1.5 + cGMP [N=2]
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator
(S1.5 and cGMP). The increasing concentrations were plotted in order resulting in a
sigmoidal curve of PKG-Iα E292A activation in the presence of cGMP, S1.5, cGMP + 1
µM S1.5, S1.5 + 100 nM cGMP.

Vmax
(µmol x min-1 x mg-1)
Vmin
(µmol x min-1 x mg-1)
Fold Activation
nh
ka [µM]

cGMP

S1.5
1.98 ± 0.06

cGMP + 1µM
S1.5
2.56 ± 0.031

S1.5 + 100
nM cGMP
-

3.02 ± 0.012
0.08 ± 0.012

0.19 ± 0.07

0.21 ± 0.03

-

35.96
1.45 ± 0.03
0.10 ± 0.04

10.63
2.31 ± 0.44
2.93 ± 0.69

12.2
1.51 ± 0.11
0.12 ± 0.13

-

Table 3.5.1. Kinetic constants derived from the activation curves comparing
co-activation of PKG Iα E292A with S1.5 and cGMP
Displayed are the kinetic variables determined from the kinetic analysis in Figure
3.6.1. The experimental conditions are listed in the top row and their corresponding
kinetics are in their respective columns. Vmax corresponds the percentage of maximal
cGMP velocity of each curve, nh corresponds to the hill coefficient of the curve, and the
Ka is the association constant of substrate binding for each curve.
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3.6 Efficacy of S1.5 Activation of the Mutant PKG Iα C42S
Due to the proximity of the Switch helix binding site to the cGMP B-site it was
hypothesized that the cGMP binding site-B and the S-tide binding site (nest) interact. To
explore this potential interaction, we determined that mutant enzyme models would be
an effective experimental approach. The C42S mutant form of PKG Iα has been
determined to have diminished activation kinetics with cGMP, demonstrating that the
mutation disrupts the pathway in which cGMP activates the enzyme (Sheehe et.al.,
2018). We incubated this enzyme with S1.5 to test its activation kinetics. If the two sites
communicate, the activation kinetics for S1.5 with C42S would display the marked shift
in Vmax and Ka. To test this hypothesis a series of kinetic assays were performed
comparing the activity of S1.5 and cGMP. Statistical analysis was performed on the
resulting data by plotting reaction velocity against the logarithm of activator
concentration with a nonlinear regression curve fit to determine the kinetic profile of
each type of activation. Shown below are a graph and a table displaying the activation
curve and the kinetic variables calculated resulting from the experiments. (Figure
3.6.1., Table 3.6.1.) PKG C42S shows a remarkable decline in kinetic activity as
previously reported (Sheehe et.al., 2018). Not only the Ka for cGMP is shifted 3-fold
shifted from 140 µM (WT) to 450 µM (C42S), the Vmax is also 2-fold reduced from 4
µmol(W15-p)/min*mg(PKG) to 2 µmol(W15-p)/min*mg(PKG). Taken together the
overall catalytic activity of C42S is less than 10% compared to WT at half maximal
activity and approximately 30-50% of full strength of WT. these findings are in
agreement with our previously published values. In contest however, the activation
kinetics of S1.5 are indistinguishable between C42S and WT. Apparently S1.5 activates
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C42S with the same potency and efficacy from WT. These results indicate that the S1.5
binding site operates independently from the cGMP mediated mechanism of action.
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Figure 3.6.1. Activation curves comparing cGMP (N=2) and S1.5 (N=6) with
the PKG Iα C42S mutant V.S. cGMP (N=6) and S1.5 (N=8) activation of PKG
Iα WT.
The reported Y-axis units are velocity in µmols of phosphorylated substrate (w15-p) per
minute mg of PKG-Iα and X-axis units are logarithmic molar concentration of activator
(S1.5 and cGMP). The increasing concentrations were plotted in order resulting in a
sigmoidal curve of PKG-Iα C42S mutant and wild type activation. The red curves
represent wild type activation and blue represents C42S activation.

cGMP WT

S1.5 WT

S1.5 C42S

cGMP C42S

Vmax
(µmol x min-1 x mg-1)

4.0 ± 0.01

2.31 ± 0.03

2.04 ± 0.02

2.41 ± 0.04

Vmin
(µmol x min-1 x mg-1)

0.44 ± 0.01

0.65 ± 0.04

0.11± 0.02

0.08 ± 0.04

Fold Activation
nh

9.05
1.48 ± 0.03

3.29
2.48 ± 0.34

19.07
2.23 ± 0.13

31.32
1.67 ± 0.13

Ka [µM]

0.14 ± 0.04

5.86 ± 0.73

4.49 ± 0.29

0.46 ± 0.53

Table 3.6.1. Kinetic constants derived from the activation curves comparing
cGMP and S1.5 activation of PKG Iα C42S mutant.
Displayed are the kinetic variables determined from the kinetic analysis in Figure 3.5.1.
The experimental conditions are listed in the top row and their corresponding kinetic
variables are in their respective columns. Vmax corresponds the maximal velocity of each
curve, nh corresponds to the hill coefficient of the curve, and the Ka is the activation
constant of each curve.
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4.0 DISCUSSION AND FUTURE DIRECTIONS
In this thesis we explored the necessary conditions for the concerted activation of
PKG Iα using cGMP and peptide analogs derived from the SW domain with the goal to
prove or disprove the structure activity relationship between the nucleotide and peptide
binding sites. To accomplish these goals, we employed site-specific mutagenesis,
secondary structure analysis via circular dichroism spectroscopy, and protein kinase
activity assays using the P81 phosphoryl transfer assays. As a result we determined the
optimal conditions for kinetic assays, we uncovered the kinetic profile of new PKG Iα
activators and gained detailed insights into the complex interaction between switch helix
and cGMP mediated activation of PKG Iα.
The first portion of this thesis was devoted to understanding the requirements of
activating PKG Iα with S-tides in relationship to cGMP. Through surface plasmon
resonance analysis of S-tide association kinetics it was discovered that S-tides require at
least 10 minutes to reach peak bound state (Moon et.al., 2015). This discovery warranted
an adaptation of the P81 phosphoryl transfer assay where we implemented a 30-minute
preincubation at 30⁰C (reaction temperature) to ensure full binding of the S-tide for
each reaction. We compared the cGMP and S1.5 activation with and without the
preincubation and determined that the addition of preincubation did not affect cGMP
activation but was necessary for S1.5 activation.
After the discovery of the switch helix domain of PKG and S-tide activators the
idea of using this as a novel drug target was the logical progression for the Dostmann
laboratory. S1.5 is the most potent switch helix analog to date, discovered through
careful N and C-terminal truncations, further shortening of the peptide resulted in
decreased activity, therefore building upon this peptide was the next step in improving
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activity (Moon et.al, 2015). Molecular modeling was employed to determine the structure
of a peptide that would interact with the switch helix binding site and the adjacent cGMP
B-site. We determined there was a need for intermediary peptides with sequential Cterminus modification. These consisted of S1.5 minus the three C-terminal amino acids
(S2.5) and the addition of a cysteamine linker (S3.5) (Figure 3.3.1). Both peptides
resulted in sequential rightward shifts in Ka meaning they had decreased activity. This
was contrary to the hypothesis. We employed secondary structure analysis of S2.5 and
S1.5 to determine if the subtraction of the amino acids was affecting the α-helicity of the
peptides, we determined it was not. Therefore, we cannot explain the decreased activity
that easily. These results have caused us to rethink the possible role of the B-site in Stide activation and caused us to peruse structural analysis of the B-site with regards to Stide activation to elucidate what is happening. The S3.5 peptide requires further
exploration and we have concluded experimentation with S3.5 and mutant forms of PKG
Iα would serve as way to increase our understanding of the B-site and S-tide activation.
We would also like to follow these experiments with surface plasmon resonance assays to
determine if S2.5 and S3.5 have different binding and dissociating kinetics than S1.5
which could help explain the shift in the data.
Once we established the need for more exploration of the B-site with respect to
S1.5 activation we determined a set of experiments employing activator combination
assays and mutant forms of PKG Iα would give us valuable insight into the mechanisms
at play. To determine the co-dependency between the two mechanisms we performed
combination assays where we used both activators to activate PKG Iα WT. The results of
this experiment showed high basal activity and decrease in potency via a rightward shift
in the Ka when cGMP was added to an S1.5 assay. These results point to some
interference between the two pathways of activation. The interference may be caused by
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a conformational change of PKG that effects switch helix activity. This led us to believe
that the cGMP B-site is potentially acting as a site of regulation for the switch helix
binding site and prompted us to use the E292A mutant form of PKG Iα which is a B-site
knock out to determine the role of the B-site when performing a combination assay. We
devised a series of experiments with the E292A mutant first to determine the kinetics of
cGMP and S1.5 activation with this mutant followed by activator combination assays.
The results of the normal activations established that the E292A mutation does not affect
either form of activation compared to PKG Iα WT. The combination assay results showed
that the cGMP + s1.5 experiment was not affected by the mutation but the S1.5 + cGMP
experiment showed an even more significant decrease in potency from the WT
combination assay. This is contrary to the hypothesis that the B-site is affecting switch
helix binding, if this was the case the Ka would not have been shifted. This data set only
represents an N=2 due to a world-wide shortage of the filter paper that this assay is
based off and therefore requires further testing. In the future this assay will be repeated
and with higher S1.5 concentrations to reach maximal activity so the kinetic profile could
be more accurately evaluated. We would like to follow this up with the E167A mutant
which is being produced at the time of this thesis completion. E167A is an A-site
knockout which is a dead enzyme, if S1.5 can activate E167A it would support the
findings that S1.5 activation is rather cGMP independent.
To help determine if the cGMP and S1.5 activation mechanisms are co-dependent
is we used the C42S mutant form of PKG Iα, which has a known degradation of cGMP
activation when compared to PKG Iα WT. We performed kinase assays and determined
that the S1.5 activation was normal and was not affected like cGMP. This result shows
supports the rejection of the central hypothesis and the idea that S-tide mediated
activation is cGMP independent.
63

This research serves as a platform for future drug development in the critical field
of cardiovascular health. PKG is known for its role in smooth muscle relaxation and is
the primary effector of the nitric oxide pathway. The nitric oxide pathway has been a
major target for antihypertension drugs since the advent of the nitro glycerin
therapeutics. PKG would be a prime target for this purpose but due to localization in
other areas of the body the problem of off target effects has been the major deterrent.
The discovery of the S-tides used in this work serve to be the first isoform specific drug
target for PKG Iα which would localize the effect of PKG activation to vascular smooth
muscle. The further development of these S-tides could usher in a new class of
antihypertension agents.
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